QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
(Address of principal executive offices) |
(Zip Code) | |
( | ||
(Registrant’s telephone number, including area code) |
Title of each class |
Trading Symbol |
Name of each exchange on which registered | ||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
☒ | Smaller reporting company | |||||
Emerging growth company |
Exhibit Number |
Description | |
31.1* | Certification of Principal Executive Officer pursuant to Exchange Act rules 13a-14 or 15d-14. | |
31.2* | Certification of Principal Financial Officer pursuant to Exchange Act rules 13a-14 or 15d-14. | |
104 | Cover Page Interactive Data File—the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
* | Filed herewith. |
ALLENA PHARMACEUTICALS, INC. | ||||||
Date: November 12, 2021 | By: | /s/ Louis Brenner | ||||
Louis Brenner, M.D. Chief Executive Officer and Director (Principal Executive Officer) | ||||||
Date: November 12, 2021 | By: | /s/ Richard Katz | ||||
Richard Katz, M.D. Chief Financial Officer (Principal Financial and Accounting Officer) |